Osteoarthritis
- PMID: 39948092
- DOI: 10.1038/s41572-025-00594-6
Osteoarthritis
Abstract
Osteoarthritis is a heterogeneous whole-joint disease that can cause pain and is a leading cause of disability and premature work loss. The predominant disease risk factors - obesity and joint injury - are well recognized and modifiable. A greater understanding of the complex mechanisms, including inflammatory, metabolic and post-traumatic processes, that can lead to disease and of the pathophysiology of pain is helping to delineate mechanistic targets. Currently, management is primarily focused on alleviating the main symptoms of pain and obstructed function through lifestyle interventions such as self-management programmes, education, physical activity, exercise and weight management. However, lack of adherence to known effective osteoarthritis therapeutic strategies also contributes to the high global disease burden. For those who have persistent symptoms that are compromising quality of life and have not responded adequately to core treatments, joint replacement is an option to consider. The burden imparted by the disease causes a substantial impact on individuals affected in terms of quality of life. For society, this disease is a substantial driver of increased health-care costs and underemployment. This Primer highlights advances and controversies in osteoarthritis, drawing key insights from the current evidence base.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: D.J.H. is the editor of the osteoarthritis section for UpToDate and co-Editor in Chief of Osteoarthritis and Cartilage. D.J.H. provides consulting advice on scientific advisory boards for Haleon, TLCBio, Novartis, Tissuegene, Sanofi and Enlivex. A.-M.M. is co-Editor in Chief of Osteoarthritis and Cartilage. A.-M.M. provides consulting services or serves on advisory boards for Averitas, Orion, LG, Novartis and Eli Lilly. T.N. is a deputy editor of Osteoarthritis and Cartilage and provides consulting services for Novartis and Eli Lilly. All other authors declare no competing interests.
References
-
- Hunter, D. J., March, L. & Chew, M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet 396, 1711–1712 (2020). - PubMed
-
- Wieland, H. A., Michaelis, M., Kirschbaum, B. J. & Rudolphi, K. A. Osteoarthritis — an untreatable disease? Nat. Rev. Drug Discov. 4, 331–344 (2005). - PubMed
-
- Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745–1759 (2019). - PubMed
-
- Kraus, V. B., Blanco, F. J., Englund, M., Karsdal, M. A. & Lohmander, L. S. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr. Cartil. 23, 1233–1241 (2015).
-
- Whittaker, J. L., Runhaar, J., Bierma-Zeinstra, S. & Roos, E. M. A lifespan approach to osteoarthritis prevention. Osteoarthr. Cartil. 29, 1638–1653 (2021).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
